Oasmia Pharmaceutical AB
Quick facts
Phase 3 pipeline
- Paclical® · Oncology
Paclical is a formulation of paclitaxel, a microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: